Sponsor Dossier
Lupin
Sponsor Dossier for Lupin. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ABACAVIR/LAMIVUDINE
- Brand: AMLODIPINE-LUPIN
- Brand: APIXABAN
- Brand: APO-LANSOPRAZOLE ODT
- Brand: ARX-FENOFIBRATE
- Brand: ARX-GLICLAZIDE
- Brand: ARX-MOXONIDINE
- Brand: Bella
About
Lupin is an Australian Private Company with ABN 97 112 038 105, registered in Victoria. The entity status is active.
Portfolio
Lupin has 74 brands on the ARTG, of which 43 are indexable and 41 carry a Product Information document. 33 brands are PBS-listed, 3 have a PBAC outcome on record, and 0 have an AusPAR on record. Notable brands include ABACAVIR/LAMIVUDINE, AMLODIPINE-LUPIN, APIXABAN, APO-LANSOPRAZOLE ODT, ARX-FENOFIBRATE, ARX-GLICLAZIDE, ARX-MOXONIDINE, Bella, CELECOXIB, CEPHALEXIN, DAPAGLIFLOZIN, DESVENLAFAXINE.
Therapeutic focus
— Cardiology: 17 brands — Reproductive Health: 13 brands — Neurology: 10 brands — Psychiatry: 8 brands — Infectious Disease: 8 brands — Endocrinology: 7 brands — Gastroenterology: 3 brands — Ophthalmology: 3 brands — Renal: 1 brand — Musculoskeletal: 1 brand — Immunology: 1 brand — Respiratory: 1 brand — Pain Management: 1 brand
PBS footprint
33 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2024-11-01, across 3 brands with a PBAC outcome on record.